Scholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal ...

Scholar Rock (SRRK) announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial will be presented in multiple clinical ...

Scholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy ...

CAMBRIDGE, Mass., February 25, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

Scholar Rock (NASDAQ:SRRK – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on ...

AlphaQuest LLC decreased its position in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 97.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The ...

Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

TD Cowen analyst Marc Frahm maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) today. The company’s shares closed last ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

The first new album in five years from Car Seat Headrest has been previewed with 11-minute single "Gethsemane." ...